Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Provided By GlobeNewswire
Last update: Aug 8, 2024
Investigational New Drug (IND) application for CLN-978 in systemic lupus erythematosus (SLE) remains on track to be filed in third quarter of 2024
Company to pursue rheumatoid arthritis (RA) as second autoimmune indication for CLN-978 development
Read more at globenewswire.com
